Division of Endocrinology and Diabetology, Medical University of Graz, 8010 Graz, Austria.
Division of Gastroenterology and Hepatology, Medical University of Graz, 8010 Graz, Austria.
Biomolecules. 2021 Apr 14;11(4):574. doi: 10.3390/biom11040574.
The EndoBarrier™ medical device is a duodenal-jejunal bypass liner designed to mimic the effects of gastric bypass surgery to induce weight loss and glycaemic improvement. In this study, 10 participants with type 2 diabetes mellitus (T2DM), a mean body mass index (BMI) of 43.3 ± 5.0 (kg/m) and a mean glycated haemoglobin A1c (HbA1c) of 60.6 ± 8.6 mmol/mol were examined at baseline (before implantation of EndoBarrier™), 4 weeks after implantation, at 36 weeks (right before explantation) and 24 weeks after the removal of the device to explore the short and long-term effects on glucose metabolism. Besides a significant reduction in body weight and fat mass, EndoBarrier™ treatment significantly improved insulin sensitivity during Botnia clamp investigations after four weeks of implantation. The beneficial effects decreased over time but remained significant 24 weeks after removal of the device.
EndoBarrier™ 医疗器械是一种十二指肠空肠旁路衬垫，旨在模拟胃旁路手术的效果，以诱导体重减轻和血糖改善。在这项研究中，10 名 2 型糖尿病（T2DM）患者，平均体重指数（BMI）为 43.3±5.0（kg/m），平均糖化血红蛋白 A1c（HbA1c）为 60.6±8.6 mmol/mol，在基线（植入 EndoBarrier™ 之前）、植入后 4 周、36 周（在取出之前）和 24 周后进行检查，以探索对葡萄糖代谢的短期和长期影响。除了体重和脂肪量的显著减轻外，EndoBarrier™ 治疗在植入后 4 周的 Botnia 夹闭研究中显著改善了胰岛素敏感性。随着时间的推移，这些有益效果逐渐减弱，但在取出装置 24 周后仍然显著。
